First Asia Pacific Symposium on Acute Myeloid Leukaemia - from Biology, Translational Research to Clinical Trials and Advanced Practices

HK Time (GMT+8)	Rundown
17:30 – 20:00	Welcoming reception *Light refreshments and beverages will be provided

HK Time (GMT+8)	Rundown	Speakers / Editors / Discussion Leaders	Chairman / Moderators
9:00 am - 9:05 am	Opening Remarks	Prof. Eric Tse Associate Dean (Research), LKS Faculty of Medicine, The University of Hong Kong
9:05 am - 9:10 am	Welcoming Remarks	Prof. Anskar Y.H. Leung Prof. Eric C.W. So
Session 1: AML and Leukaemia Stem Cells
9:10 am - 9:40 am	Lecture #1 Treatment of AML: Focus on Disease Variation	Prof. Bob Löwenberg	Prof. Anskar Y.H. Leung
9:40 am - 10:10 am	Lecture #2 The LSC and Their Niche	Prof. Dominique Bonnet	Prof. Anskar Y.H. Leung
10:10 am - 10:25 am	Short Talk #1 Understanding the Genomic Landscape in Acute Myeloid Leukaemia: Identification of RNA Fusion Genes and DNA Variants Via Next-Generation Sequencing	Dr. Chieh Hwee Ang	Prof. Anskar Y.H. Leung
10:25 am - 10:55 am	Tea Break
Session 2: NPM1 Mutated AML and Therapeutic Advances
10:55am - 11:25am	Lecture #3 NPM1-mutated AML: From Bench to Bedside	Prof. Brunangelo Falini	Prof. Paresh Vyas
11:25 am - 11:55 am	Lecture #4 Longitudinal Changes in Bone Marrow Constituents with Hypomethylating Agents in MDS/AML	Prof. John Pimanda	Prof. Paresh Vyas
11:55 am - 12:10 pm	Short Talk #2 A Flu5Bu2Cy Reduced-Intensity Conditioning Protocol for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients in Taiwan: A Single-center Experience	Dr. Jui-Che Chen	Prof. Paresh Vyas
12:10 pm - 2:25 pm	Lunch
Session 3: FLT3 Mutated AML and Therapeutic Advances
2:25 pm - 2:55 pm	Lecture #5 Management of Molecular and Morphological R/R Disease in FLT3m+ AML (Sponsored by Astellas Pharma Hong Kong Co., Ltd)	Prof. Mark Levis	Prof. Brian Huntly
2:55 pm - 3:25 pm	Lecture #6 Combination of Quizartinib and Omacetaxine Mepesuccinate Remodels Proteostasis and Triggers Inflammatory Response in FLT3-ITD AML	Prof. Anskar Y.H. Leung	Prof. Brian Huntly
3:25 pm - 3:40 pm	Short Talk #3 Histone Hypoacetylation-driven CD9 Repression Arrests Differentiation and Evades Immunosurveillance in Pediatric Acute Myeloid Leukemia	Dr. Yaqun Xu	Prof. Brian Huntly
Session 4: TP53 Mutated AML and Therapeutic Advances
3:40 pm - 4:10 pm	Lecture #7 Prognostic Impact of Mutant TP53 Variant Allelic Frequency in Acute Myeloid Leukemia	Dr. Hsin-An Hou	Prof. Ruud Delwel
4:10 pm - 4:40 pm	Lecture #8 Targeting Mutant p53 Acute Myeloid Leukemias (AML) by Conformational Reactivation of Y220C mutant p53 and by Degradation of Upregulated c-MYC	Dr. Michael Andreeff	Prof. Ruud Delwel
4:40 pm - 4:55 pm	Short Talk #4 Decitabine and Immune Activation in TP53 Mutated MDS/AML	Dr. Nelson Ng	Prof. Ruud Delwel

HK Time (GMT+8)	Rundown	Speakers / Editors / Discussion Leaders	Chairman / Moderators
Session 5: Epigenetic Mechanisms for Haematopoietic Ageing and AML
9:00 am - 9:30 am	Lecture #9 Epigenetic Remodeling Underlies the Development of Down Syndrome-related Acute Megakaryoblastic Leukemia	Prof. Atsushi Iwama	Prof. Eric C.W. So
9:30 am - 10:00 am	Lecture #10 Altered Transcriptional Programmes in AML: the Role of Aberrant Gene Regulatory Complexes (GRC)	Prof. Brian Huntly	Prof. Eric C.W. So
10:00 am - 10:15 am	Short Talk #5 HOPX Plays a Tumor Suppressor Role in MN1-induced Acute Myeloid Leukemia	Dr. Lin Chien-Chin	Prof. Eric C.W. So
Session 6: Epitranscriptomics and Chromatin Domains in AML
10:15 am - 10:45 am	Lecture #11 RNA Modifications in Acute Myeloid Leukemia	Prof. Jianjun Chen	Prof. Kristian Helin
10:45 am - 11:15 am	Lecture #12 Evil Genes and Enhancers in Acute Myeloid Leukemia	Prof. Ruud Delwel	Prof. Kristian Helin
11:15 am - 11:30 am	Short Talk #6 Therapeutic Targeting of a Novel Ubiquitination-dependent Mechanism for pTEFb Activation in AML	Dr. Ngai Cheung	Prof. Kristian Helin
11:30 am - 12:00 pm	Tea Break
Session 7: Transcriptomics and Metabolism in AML
12:00 pm - 12:30 pm	Lecture #13 Metabolic Dependencies in Clonal Hematopoiesis	Dr. Steven Chan	Prof. John Pimanda
12:30 pm - 1:00 pm	Lecture #14 Comprehensive Transcriptomic Profiles and Metabolic Perturbations in Acute Myeloid Leukemia	Prof. Yang Shen	Prof. John Pimanda
1:00 pm - 3:00 pm	Meet the Expert Lunch
Session 8: Therapeutic Vulnerabilities in Myeloid Malignancies
3:00 pm - 3:30 pm	Lecture #15 WNK1 Signalling Regulates Amino Acid Transport and mTORC1 Activity to Sustain AML Growth	Prof. Kristian Helin	Prof. Dominique Bonnet
3:30 pm - 4:00 pm	Lecture #16 Transposable Elements as Novel Therapeutic Targets for PARPi-induced Synthetic Lethality in Haematological Malignancies with PcG Epigenetic Mutations	Prof. Eric C.W. So	Prof. Dominique Bonnet
4:00 pm - 4:15 pm	Short Talk #7 Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy Between Hypomethylating Agents and SUMOylation Blockade in MDS/AML	Dr. Chris Jolly	Prof. Dominique Bonnet
4:15 pm - 6:15 pm	Poster Session

HK Time (GMT+8)	Rundown	Speakers / Editors / Discussion Leaders	Chairman / Moderators
Session 9: Combination Treatment in AML and Therapeutic Mechanisms
9:00 am - 9:30 am	Lecture #17 Venetoclax Resistance and New Therapeutic Directions	Prof. Andrew Wei	Prof. Xiaojun Huang
9:30 am - 10:00 am	Lecture #18 Combination Treatment in AML and Therapeutic Mechanisms	Prof. Paresh Vyas	Prof. Xiaojun Huang
10:00 am - 10:45 am	Meet the Editors - Nature Cell Biology and Lancet Haematology	Editors: Dr. Lan-Lan Smith Dr. Zhe Wang	Chairman: Prof. Hinrich Gronemeyer
10:45 am - 11:15 am	Tea Break
Session 10: HSCT and Personalized Treatment for AML
11:15 am - 11:45 am	Lecture #19 Hematopoietic Cell Transplant for AML: Where We Are and Where to Go	Prof. Xiaojun Huang	Prof. Dr. Christoph Röllig
11:45 am - 12:15 pm	Lecture #20 Big Data for Novel Therapeutic Strategies in Myeloid Malignancies	Prof. Jeffrey Tyner	Prof. Dr. Christoph Röllig
12:15 pm - 12:30 pm	Short Talk #8 Integration of Inflammation, Cell-type Composition, and Immune Signatures in the Bone Marrow Reveals Novel Prognostic Subgroups in Myelodysplastic Syndromes	Dr. Mohammad Mahdi Karimi	Prof. Dr. Christoph Röllig
12:30 pm - 2:30 pm	Lunch
Session 11: Evolving Treatment Landscape in AML
2:30 pm - 3:00 pm	Lecture #21 Venetoclax Based Regimens in AML: Understanding Resistance and Building Novel Combinations	Prof. Naval Daver	Prof. Andrew Wei
3:00 pm - 3:30 pm	Lecture #22 AML Treatment in 5 Years – What Are We Anticipating? (Sponsored by AbbVie Hong Kong)	Prof. Dr. Christoph Röllig	Prof. Andrew Wei
3:30 pm - 3:45 pm	Short Talk #9 CD38 Enzymatic Activity Promotes Hematopoietic Stem Cell Dormancy	Prof. Tatyana Grinenko	Prof. Andrew Wei
Session 12: Other Important Haematological Malignancies
3:45 pm - 4:15 pm	Lecture #23 CAR-T and T Cell Re-directional Therapies - A New Era in Myeloma	Prof. Joy Ho	Prof. Anskar Y.H. Leung
4:15 pm - 5:15 pm	Panel Discussion: Major Research and Clinical Challenge in AML	Discussion Leaders: Prof. Stephen Ekker Prof. Hinrich Gronemeyer Prof. Paresh Vyas	Prof. Anskar Y.H. Leung
5:15 pm - 5:30 pm	Prize Ceremony Closing Remarks	Prof. Anskar Y.H. Leung Prof. Eric C.W. So

Dr. Michael Andreeff

Professor of Medicine and Endowed Haas Chair in Genetics;
Chief, Section of Molecular Hematology & Therapy;
Director, NCI CCSG Flow Cytometry/Image Analysis Core Facility;
Co-Director, NCI CCSG Hematological Malignancies Program;
Medical Director,
Bone Marrow Aspiration Clinic

Prof. Dominique Bonnet

Principal Group Leader,
The Francis Crick Institute

Dr. Steven Chan

Senior Scientist and Staff Physician,
Princess Margaret Cancer Centre

Prof. Jianjun Chen

Professor and Chair,
Department of Systems Biology,
Beckman Research Institute of
City of Hope

Prof. Naval Daver

Director,
Leukemia Research Alliance Program,
Professor,
Department of Leukemia,
MD Anderson Cancer Center

Prof. Ruud Delwel

Professor of Molecular Leukemogenesis,
Department of Hematology,
Erasmus MC

Prof. Brunangelo Falini

Full Professor of Hematology,
M.D.,
University of Perugia, Italy

Prof. Kristian Helin

Chief Executive and President,
Professor in Epigenetics and Cancer,
The Institute of Cancer Research

Prof. Joy Ho

Alan Ng Professor in Haematology, University of Sydney;
Head of Department, Haematology and
Director of Research,
Institute of Haematology, Royal Prince Alfred Hospital

Dr. Hsin-An Hou

Professor, Division of Hematology,
Department of Internal Medicine,
National Taiwan University (NTU) Hospital, NTU

Prof. Xiaojun Huang

Member of Chinese Academy of Engineering;
Chairman of Peking University Institute of Hematology, PUPH;
Director of National Clinical Research Center for Hematologic Diseases, P.R.China;
Fellow of the Chinese Academy of Medical Sciences;
Foreign Corresponding Member of the French Academy of Medicine

Prof. Brian Huntly

Professor of Leukaemia Stem Cell Biology,
University of Cambridge

Prof. Atsushi Iwama

Professor,
Division of Stem Cell and Molecular Medicine,
Center for Stem Cell Biology and Regenerative Medicine,
The Institute of Medical Science, The University of Tokyo

Prof. Anskar Y.H. Leung

Professor, Chair of Haematology,
Li Shu Fan Medical Foundation Professor in Haematology,
Department of Medicine,
School of Clinical Medicine,
LKS Faculty of Medicine,
The University of Hong Kong

Prof. Mark Levis

Professor of Oncology/Director,
Adult Leukemia Service/Co-Division Director,
Division of Hematologic Malignancies,
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

Prof. Bob Löwenberg

Professor of Hematology,
Erasmus University Medical Center,
Rotterdam, Netherlands

Prof. John Pimanda

Consultant Haematologist,
Prince of Wales Hospital;
Head, Stem Cell Laboratory,
Lowy Cancer Research Centre,
School of Biomedical Sciences,
UNSW Sydney, Australia

Prof. Dr. Christoph Röllig

Program Lead Hematology,
Consultant Hematologist,
Head of Clinical Trial Unit,
Secretary of SAL Study Group,
Universätsklinikum Dresden,
Germany

Prof. Yang Shen

Chief Doctor, Professor,
Deputy Director of the Department of Hematology,
Ruijin Hospital, School of Medicine,
Shanghai Jiaotong University

Prof. Eric C.W. So

Professor and Chair in Leukemia Biology,
Department of Haematology,
King’s College London;
Professor, Specialist Medicine,
King’s College Hospital NHS Trust

Prof. Jeffrey Tyner

Professor,
Department of Cell, Developmental & Cancer Biology,
Knight Cancer Institute,
Oregon Health & Science University

Prof. Paresh Vyas

Clinical Academic and Deputy Director,
The MRC Molecular Haematology Unit (MHU),
Weatherall Institute of Molecular Medicine (WIMM),
The University of Oxford

Prof. Andrew Wei

Department of Clinical Haematology,
Peter MacCallum Centre and Royal Melbourne Hospital,
Walter and Eliza Hall Institute of Medical Research